Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 405-414

  Liu, Xiao Qian ^a   Lu, Kang ^a   Feng, Li Li ^a   Ding, Mei ^a   Gao, Jun Ming ^a   Ge, Xue Ling ^a   Wang, Xin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Forkhead box P3; Indoleamine 2,3 dioxygenase 1; Non Hodgkin lymphoma; Prognosis; Regulatory T cell

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; LACTATE DEHYDROGENASE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CD4+ CD25+ T LYMPHOCYTE; CLINICAL FEATURE; COCULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MICE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN; UP-REGULATION; YOUNG ADULT;

EID: 84904330032     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.804917     Document Type: Article

References (51)

1. Curti A, Trabanelli S, Salvestrini V., et al The role of indoleamlne 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009;113:2394-2401.
2. Ninomiya S, Hara T, Tsurumi H., et al Indoleamlne 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011;90:409-416.
3. Van Loo P., Tousseyn T, Vanhentenrijk V., et al T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010;95:440-448.
4. Ninomiya S, Hara T, Tsurumi H., et al Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2012;53:1143-1145.
5. Mellor AL, Munn DH Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-473. (Pubitemid 29476077)
6. Liu X, Liu Y, Ding M., et al Reduced expression of indoleamine 2,3-dioxygenase participates in pathogenesis of preeclampsia via regulatory T cells. Mol Med Rep 2011;4:53-58.
7. Maby-El Hajjami H, Ame-Thomas P, Pangault C, et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res 2009;69:3228-3237.
8. Mellor AL, Keskin DB, Johnson T, et al Cells expressingindoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002; 168: 3771-3776. (Pubitemid 34298376)
9. Frumento G, Rotondo R, Tonetti M., et al Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-468.
10. Grohmann U, Fallarino F, Puccerti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24:242-248. (Pubitemid 36555962)
11. Sznurkowski JJ, Zawrocki A, Emerich I., et al Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol 2011;122:307-312.
12. Curti A, Trabanelli S, Onofri C., et al Indoleamine 2, 3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010;95:2022-2030.
13. Curti A, Pandolfi S, Valzasina B., et al Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25 + T regulatory cells. Blood 2007;109:2871-2877. (Pubitemid 46482083)
14. Levina V, Su Y, Gorelik E. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol 2012; 2012:173029.
15. Mezrich JD, Fechner JH, Zhang X, et al An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010,185:3190-3198.
16. Wang J, Ke XY The four types of Tregs in malignant lymphomas. J Hematol Oncol 2011;4:50.
17. Valzasina B, Piconese S, Guiducci C., et al Tumor-induced expansion of regulatory T cells by conversion of CD4 + CD25-ymphocytes is thymus and proliferation independent. Cancer Res 2006;66:4488-4495.
18. Thorstenson KM, Khoruts A. Generation of anergic and potentially immunoregulatory CD25 + CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 2001;167:188-195. (Pubitemid 32567777)
19. Mahnke K, Qian Y, Knop J., et al Induction of CD4+/ CD25 + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003,101:4862-4869. (Pubitemid 36857748)
20. Sharma S, Yang SC, Zhu L, et al Tumor cyclooxygenase-2/ prostaglandin E2-dependent promotion of FOXP3 expression and CD4 + CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-5220. (Pubitemid 40827331)
21. Lu LF, Lind EF, Gondek D.C., et al Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006;442: 997-1002. (Pubitemid 44330250)
22. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-745. (Pubitemid 46348742)
23. Chen W, Jin W, Hardegen N., et al Conversion of peripheral CD4 + CD25-naive T cells to CD4 + CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-1886. (Pubitemid 38032120)
24. Quatromoni JG, Morris LF, Donahue T.R., et al T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3. J Hematol Oncol 2011;4:48.
25. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-787. (Pubitemid 351707693)
26. Feng LL, Gao IM, Li P.P., et al IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma. J Clin Immunol 2011;31:1084-1094.
27. Mittal S, Marshall NA, Duncan L, et al Local and systemic induction of CD4 + CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-5370.
28. Felcht M, Heck M, Weiss C, et al. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol 2012;167:348-358.
29. Kim WY, Jeon YK, Kim T.M., et al Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009;20:1688-1696.
30. Lee NR, Song EK, Jang K.Y., et al Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-256. (Pubitemid 351193916)
31. Cheson BD, Horning SI, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
32. Lob S, Konigsrainer A, Zieker D., et al IDO1 and ID02 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153-157.
33. Ogawa K, Hara T, Shimizu M., et al Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methylrryptophan, an inhibitor of indoleamine 2,3-dioxygenase. Cancer Sci 2012;103:951-958.
34. Hoshi M, Ito H, Fujigaki H., et al Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. Leuk Res 2009;33:39-45.
35. Ferdinande L, Decaestecker C, Verset L., et al Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012;106:141-147.
36. Yu J, Sun I, Wang S.E., et al Upregulated expression of indoleamine 2,3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol 2011;2011:469135.
37. Karanikas V, Zamanakou M, Kerenidi T., et al Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007;6:1258-1262. (Pubitemid 351590380)
38. Inaba T, Ino K, Kajiyama H., et al Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009;115:185-192.
39. Nakamura T, Shima T, Saeki A., et al Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-881. (Pubitemid 46691826)
40. Muller AI, DuHadaway IB, Donover P.S., et al Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemotherapy. Nat Med 2005;11:312-319. (Pubitemid 40460560)
41. Mellor AL, Munn DH Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-5813. (Pubitemid 36682557)
42. Lee GK, Park HI, Macleod M, et al Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002; 107:452-460. (Pubitemid 36693650)
43. Catani L, Sollazzo D, Trabanelli S., et al Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Ann Hematol 2013;92:67-78.
44. Munn DH, Zhou M, Attwood I.T., et al Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193. (Pubitemid 28406294)
45. Munn DH, Sharma MD, Hou D, et al Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-290. (Pubitemid 39071633)
46. Muller AI, DuHadaway IB, Chang M.Y., et al Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 2010;59:1655-1663.
47. Lee IR, Dalton RR, Messina I.L., et al Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83:1457-1466. (Pubitemid 37267829)
48. Fallarino F, Grohmann U, Hwang K.W., et al Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4: 1206-1212. (Pubitemid 37547898)
49. Sharma MD, Baban B, Chandler P., et al Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117: 2570-2582. (Pubitemid 47494358)
50. Matteoli G, Mazzini E, Iliev I.D., et al Gut CD103 + dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010;59: 595-604.
51. Han Y, Wu I, Bi L., et al Malignant B cells induce the conversion of CD4 + CD25-T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One 2011;6:e28649.